Pataday Once Daily Relief (olopatadine 0.2%)

Approved uses

Allergic conjunctivitis, ocular itching

1 drop in each affected eye QD

Itch relief is present at onset of action and still holds 16 hours after a single drop.

OFF-LABELNot in the FDA label for this product

Ocular redness of seasonal allergic conjunctivitis

1 drop in each affected eye QD, the labeled regimen, used for 10 weeks in the trial

RCT · n=260

Randomized, double-masked, placebo-controlled environmental trial across a spring grass season (N=260): on high pollen days 14% of treated patients rated redness frequency above 2 versus 31% on placebo (P<0.003), against 21% versus 47% for itching (P<0.001). The OTC Use statement on this product claims itch relief only, so redness is an unlabeled endpoint here.

Abelson MB, Gomes PJ, Vogelson CT, Pasquine TA, Gross RD, Turner FD, Wells DT, Bergamini MV, Robertson SM. Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental study. Clin Ther. 2004;26(8):1237-1248.

Contraindications

Do not use if you are sensitive to any ingredient in this product.